Reference number : 172-2020-2021-Q3-961445, amendment number : 2, agreement type : G, recipient legal name : University of Ottawa, recipient country : CA, recipient province : ON, recipient city : Ottawa|Ottawa, recipient postal code : K1N 6N5, program name english : Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives, program name french : Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D, program purpose english : Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas., program purpose french : Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires., agreement title english : Reprogramming the human genome through targeted genomic integration of synthetic DNA, agreement title french : Reprogrammation du génome humain par intégration ciblée d’ADN synthétique, agreement number : 961445, agreement value : 224200.0, agreement start date : 2021-01-01, agreement end date : 2024-04-30, description english : The overall objective of this Project is to develop the technology and expertise necessary for reprogramming the human genome through targeted integration of recombinant DNA within induced-pluripotent stem cells (iPSCs). This Project aims to leverage the innate programming of the human genome by performing integration of therapeutic genes, such as chimeric antigen receptors (CAR), into targeted sites. These tools will be key to the deployment and validation of NRC’s self-cleaving and integrating plasmid (pSCIP) technology towards engineering iPSC-derived CAR-Natural Killer (NK) cells that will prevent treatment-associated toxicity and immune-mediated adverse events and help expedite preclinical proof of concept studies for targeting solid tumors such as triple negative breast cancer., description french : Reprogrammation du génome humain par intégration ciblée d’ADN synthétique, expected results english : In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems., expected results french : À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides., additional information english : This agreement has been amended 2 time(s). The end date of this agreement has been modified by 242 days., additional information french : Cet accord a été modifié 2 fois.  La date de fin du présent accord a été changé de 242 jours., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada